Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02379585 · ClinicalTrials.gov registry record · Phase 1
Fasting on Newly Diagnosed Breast Cancer
A Phase 1 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02379585: Clinical Trial Phase 1 study, sponsored by Western Regional Medical Center.
NCT02379585 is a Phase 1 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02379585, a Phase 1 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is to see how safe the use of short-term fasting is in breast cancer patients who will receive chemotherapy before undergoing surgery and to examine if the use of short-term fasting will decrease the side effects of chemotherapy and how much a tumor shrinks while receiving chemotherapy.
Primary Outcome
Evaluate pathological complete remission rate at the time of surgery, or partial pathological response rate (defined as residual invasive disease of 1cm) at the time of surgery or at the time of biopsy upon completion of planned chemotherapy.
Interventions
- DRUG Trastuzumab
- DRUG Doxorubicin
- DRUG cyclophosphamide
- DRUG docetaxel
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Why NCT02379585 stopped before completion
NCT02379585 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT02379585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02379585 about?
NCT02379585 is a clinical study titled "Fasting on Newly Diagnosed Breast Cancer". This study is to see how safe the use of short-term fasting is in breast cancer patients who will receive chemotherapy before undergoing surgery and to examine if the use of short-term fasting will decrease the side effects of chemotherapy and how much a tumor shrinks while receiving chemotherapy.
What is the current status of trial NCT02379585?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02379585?
The interventions under investigation include: Trastuzumab (DRUG), Doxorubicin (DRUG), cyclophosphamide (DRUG), docetaxel (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02379585?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02379585's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia